News & Updates
Showing Multidisciplinary articles
Showing

Nivolumab bests ipilimumab in head-to-head melanoma trial
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.

HK data: LAI antipsychotics superior to oral antipsychotics in older patients with schizophrenia
Long-acting injectable (LAI) antipsychotics are associated with lower risks of disease relapse and mortality than oral antipsychotics in older patients with schizophrenia, a population-based study in Hong Kong has shown.

Enzalutamide-ADT a win for biochemically recurrent prostate cancer
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.





